- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04433429
Nutraceuticals and Vascular Remodelling (MALTRO)
June 12, 2020 updated by: Marcello Rattazzi
Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated With Nutraceuticals Derived From Red Yeast Rice.
Aim of the study is to assess the effect of a long-term nutraceutical multitarget approach on lipid profile, inflammatory mediators and vascular remodeling in primary cardiovascular prevention in a setting of controlled dietary habits.
The nutraceutical combination used in this study consists of a single pill containing 333 mg of RYR, equivalent to 10 mg of Monacolin K, and 30 mg of Coenzyme Q10 (CoQ10).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Padova, Italy, 35125
- Azienda Ospedaliera di Padova
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects with mild hypercholeterolemia and low-to moderate cardiovascular risk profile
Description
Inclusion Criteria:
- Total Cholesterol > 150 mg/dl and < 250 mg/dl;
- Triglycerides > 150 mg/dl and < 500 mg/dl;
- Fasting glucose < 126 mg/dl;
- Stable antihypertensive treatment (at least for 6 months) in presence of hypertension.
Exclusion Criteria:
- Total Cholesterol > 250 mg/dl
- Triglycerides > 500 mg/dl
- Previous statin therapy (last 6 months);
- Treatment with hypoglycemic agents and/or fasting glucose > 126 mg/dl;
- Chronic gastrointestinal disorders;
- Chronic kidney disease (eGFR < 60 ml/min/1.73 m2);
- Concomitant treatment with drugs potentially interfering with glucose and lipid metabolism; - History of cardiovascular diseases;
- Proven intolerance to any component of the nutraceutical product;
- Pregnancy or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
RYR plus CoQ
333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in cholesterol levels at one year
Time Frame: Baseline and one year
|
Total Cholesterol will be measured in the blood sample from each patient and expressed as mg/dl
|
Baseline and one year
|
Change from baseline in carotid intima media thickening at one year
Time Frame: Baseline and one year
|
Carotid ultrasound examination is performed at baseline and after one year to measure intima-media thickness (IMT).
IMT is defined as the distance in mm between the lumen-intima and the media-adventitia interfaces, it is measured at end diastole in the far wall of the right and left sides of the common carotid artery, the bulb and the internal carotid artery.
Carotid IMT measurements are expressed as cumulative mean of mean-IMT (m-IMT) recorded in each vascular segment .
|
Baseline and one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
December 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
June 10, 2020
First Submitted That Met QC Criteria
June 12, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Actual)
June 16, 2020
Last Update Submitted That Met QC Criteria
June 12, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3497/AO/15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on Liposcudil Plus
-
Qure Healthcare, LLCLineagenCompletedIntellectual Disability | Developmental DelayUnited States
-
University of South CarolinaAmerican Cancer Society, Inc.CompletedBreast CancerUnited States
-
The University of Tennessee, KnoxvilleNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Cherokee...CompletedObesity | Childhood ObesityUnited States
-
ResMedCompletedSleep Apnea, Obstructive | Sleep Apnea, CentralGermany
-
Alma Lasers Inc.Unknown
-
Ethicon, Inc.Completed
-
Farmaceutici Damor SpaRecruitingWounds and Injuries | Wound Infection | Wound HealItaly
-
University of TrierGerman Research FoundationCompletedFeedback, PsychologicalGermany
-
Vanderbilt University Medical CenterRecruitingBreast CancerUnited States
-
Zhejiang Cancer HospitalRecruitingBile Duct AdenocarcinomaChina